Best Forex System Download : Drug Stock Soars on FDA Nod


OPENING VIEW

	12/30/2019

A stock that yields 67% a year? Really?

If you're happy with stocks yielding you 4% or 5% a year, you don't need this. But if you want to see how we built a portfolio that now pays us a 67% cash on cash return — with no leverage, options, or gimmicks — you'll want to learn more.

Go here ASAP.

Stock Futures Churn Near Record Highs

By Patrick Martin

**Share On**

After a Christmas week full of records on Wall Street, Dow Jones Industrial Average (DJI) futures are much quieter this morning, holding modestly above fair value. Futures on the S&P 500 Index (SPX) and Nasdaq-100 Index (NDX) are signaling slightly lower opens, with volume likely to be low heading into the New Year's holiday. As far as economic data, the U.S. trade deficit in goods fell 5.4% to $63.2 billion in November.

Continue reading for more on today's market, including:

Breaking down Tesla's big week.
An FDA nod sent this drug stock soaring.
Plus, Tesla rival scores quarterly win; Goodyear nabs a "buy" rating; and AstraZeneca gets an FDA nod.

>> Continue reading...

LATEST HEADLINES

>>		The VIX Trendline Bulls Should Be Watching A volatility pop concurrent with a drop in stock prices could be a risk to bulls
>>		One Bullseye Breakout Trade Building By the Day Click to continue to advertiser's site.
>>		The Secret to Profiting with Niche Trading Click to continue to advertiser's site.
>>		The Trend Minting Millionaires -- But Who Is Really Paying? Porter Stansberry is making a concerning prediction.
>>		Nasdaq Win Streak Finally Snaps All three indexes enjoyed weekly gains during the holiday-shorted week, however

Sponsored
The safest stocks in America Like any other investor, I try to buy low and sell high... but the BIG difference with me is that I buy just one kind of stock. They sell a product that 152 million customers are virtually addicted to. And the kicker is: they are the only type of stocks mandated by law to make a profit. Check out my portfolio here.

To ensure delivery of Schaeffer's Opening View, add us to your contacts! For more information, please visit this link for further instructions.

This email was sent to phanhoa1821960.trader@blogger.com because you are a registered subscriber to Schaeffer's Opening View or have signed up to receive emails from www.schaeffersresearch.com. Don't want to receive Schaeffer's Opening View? You can unsubscribe here.

For more information about our privacy practices, please review our Privacy Policy or our Terms & Conditions.

Have a question, comment or concern? We’ll respond quickest if you call (800) 448-2080, email, or write to:

SCHAEFFER'S OPENING VIEW

enews@schaeffer.com

5151 Pfeiffer Rd. Suite 250

Cincinnati, OH, 45242 USA

800-448-2080